Sun Pharma
Pays vs peer median
×0.79
-21% premium
Sample
6
medium confidence
Last refreshed
2026-04-13
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| dermatology | ×0.79 | 6 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| phase 3 | ×0.89 | 5 |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2025 | deuterated JAK inhibitor | Concert Pharmaceuticals | alopecia areata | phase_3 | $576M | $576M |
| 2023 | alopeciaAreata | Concert Pharmaceuticals | alopeciaAreata | phase_3 | $576M | $576M |
| 2022 | acne | Nuvation Bio | acne | phase_1 | $45M | $250M |
How this is computed
For each Sun Pharma deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 6 disclosed deal premiums vs. peer medians. Raw premium 0.785, clamped to [0.7, 1.5].